Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP1 | O60894 | 2/20 | 0.55 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.55 |
| ▸ | SLC6A5 | Q9Y345 | 5/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.33 |
| ▸ | CCR10 | P46092 | 5/20 | 0.33 |
| ▸ | RET | P07949 | 2/20 | 0.33 |
| ▸ | ROS1 | P08922 | 2/20 | 0.33 |
| ▸ | FLT3 | P36888 | 2/20 | 0.33 |
| ▸ | EML4 | Q9HC35 | 2/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.33 |
| ▸ | USP5 | P45974 | 1/20 | 0.33 |
| ▸ | CALCA | P06881 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4472279 | 1.00 | RAMP1 (0.55) | RAMP1CALCRLSLC6A5DYRK1AADRB2 | |
| SCHEMBL4472276 | 0.95 | RAMP1 (0.56) | RAMP1CALCRLSLC6A5DYRK1AADRB2 | |
| SCHEMBL3314758 | 0.85 | RAMP1 (0.59) | RAMP1CALCRLSLC6A5ADRB2RET | |
| SCHEMBL5248991 | 0.85 | RAMP1 (0.59) | RAMP1CALCRLSLC6A5ADRB2CALCA | |
| SCHEMBL3314750 | 0.85 | RAMP1 (0.59) | RAMP1CALCRLSLC6A5ADRB2RET | |
| SCHEMBL3309816 | 0.85 | RAMP1 (0.58) | RAMP1CALCRLSLC6A5CCR10 | |
| SCHEMBL3309820 | 0.85 | RAMP1 (0.58) | RAMP1CALCRLSLC6A5CCR10 | |
| SCHEMBL27760084 | 0.84 | CALCRL (0.52) | RAMP1CALCRLSLC6A5DYRK1AADRB2 | |
| SCHEMBL3314129 | 0.82 | CALCRL (0.66) | RAMP1CALCRLSLC6A5ADRB2USP5 | |
| SCHEMBL3314116 | 0.82 | CALCRL (0.66) | RAMP1CALCRLSLC6A5ADRB2USP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638625-B2 | Crystalline compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-29 | — | — | US | disclosed |
| US-20080086003-A1 | 1-[4-amino-3,5-dibromo-N-[[4-(2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine-p-toluenesulphonate or other inorganic organic salts; calcitonin gene related peptide-antagonist; useful for treating headache and migraine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080086003-A1 | 1-[4-amino-3,5-dibromo-N-[[4-(2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine-p-toluenesulphonate or other inorganic organic salts; calcitonin gene related peptide-antagonist; useful for treating headache and migraine | SUCNR1, TRPC1, TRPV1 | RAMP1 629/4885CALCRL 10/4885SLC6A5 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.